Relative resistance of HIV-1 founder viruses to control by interferon-alpha.

PubWeight™: 1.55‹?› | Rank: Top 4%

🔗 View Article (PMC 3907080)

Published in Retrovirology on December 03, 2013


Angharad E Fenton-May1, Oliver Dibben, Tanja Emmerich, Haitao Ding, Katja Pfafferott, Marlen M Aasa-Chapman, Pierre Pellegrino, Ian Williams, Myron S Cohen, Feng Gao, George M Shaw, Beatrice H Hahn, Christina Ochsenbauer, John C Kappes, Persephone Borrow

Author Affiliations

1: Nuffield Department of Medicine, University of Oxford, NDM Research Building, Old Road Campus, Headington, Oxford OX3 7FZ, UK.

Articles citing this

HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science (2014) 2.38

Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature (2014) 2.20

Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction. Cell Host Microbe (2016) 1.51

Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. PLoS Pathog (2017) 1.38

CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci U S A (2015) 1.25

Host and viral determinants of Mx2 antiretroviral activity. J Virol (2014) 1.23

HIV-1 and interferons: who's interfering with whom? Nat Rev Microbiol (2015) 1.14

Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat Rev Microbiol (2015) 1.08

Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology (2016) 1.07

Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques. J Virol (2015) 1.04

Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-α Resistance. PLoS Pathog (2015) 1.03

IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology (2014) 1.01

Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. Cell Host Microbe (2014) 0.99

Innate immune responses and rapid control of inflammation in African green monkeys treated or not with interferon-alpha during primary SIVagm infection. PLoS Pathog (2014) 0.98

Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity. EBioMedicine (2015) 0.94

Factors associated with siman immunodeficiency virus transmission in a natural African nonhuman primate host in the wild. J Virol (2014) 0.94

HIV-Host Interactions: Implications for Vaccine Design. Cell Host Microbe (2016) 0.93

Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. PLoS Pathog (2016) 0.90

HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1. J Virol (2015) 0.89

Interferon-α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. PLoS Pathog (2015) 0.87

A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. J Virol (2015) 0.87

Interactions between HIV-1 and the cell-autonomous innate immune system. Cell Host Microbe (2014) 0.86

Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus. J Infect Dis (2014) 0.85

Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. Proc Natl Acad Sci U S A (2017) 0.84

Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4. MBio (2015) 0.83

Particle infectivity of HIV-1 full-length genome infectious molecular clones in a subtype C heterosexual transmission pair following high fidelity amplification and unbiased cloning. Virology (2014) 0.82

Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo. J Virol (2016) 0.81

Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? Philos Trans R Soc Lond B Biol Sci (2014) 0.81

Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance. MBio (2016) 0.80

Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users. Retrovirology (2014) 0.80

HIV: The mixed blessing of interferon. Nature (2014) 0.79

Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors. J Virol (2016) 0.78

HIV-1 Env and Nef Cooperatively Contribute to Plasmacytoid Dendritic Cell Activation via CD4-Dependent Mechanisms. J Virol (2015) 0.78

Sensing of HIV-1 Infection in Tzm-bl Cells with Reconstituted Expression of STING. J Virol (2015) 0.78

Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection. Virology (2015) 0.78

CD4 Receptor is a Key Determinant of Divergent HIV-1 Sensing by Plasmacytoid Dendritic Cells. PLoS Pathog (2016) 0.78

Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection. J Virol (2016) 0.78

Interferons and HIV Infection: The Good, the Bad, and the Ugly. Pathog Immun (2016) 0.77

Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. EBioMedicine (2016) 0.77

The Molecular Characterization of Intestinal Explant HIV Infection Using Polymerase Chain Reaction-Based Techniques. AIDS Res Hum Retroviruses (2015) 0.77

Identification of Interferon-Stimulated Genes with Antiretroviral Activity. Cell Host Microbe (2016) 0.77

HIV transmission biology: translation for HIV prevention. AIDS (2015) 0.77

Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses. Clin Transl Immunology (2015) 0.77

Transmission of Multiple HIV-1 Subtype C Transmitted/founder Viruses into the Same Recipients Was not Determined by Modest Phenotypic Differences. Sci Rep (2016) 0.76

Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function. AIDS Res Hum Retroviruses (2015) 0.76

Adapting SHIVs In Vivo Selects for Envelope-Mediated Interferon-α Resistance. PLoS Pathog (2016) 0.76

The effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model. Retrovirology (2016) 0.75

The HIV-1 transmission bottleneck. Retrovirology (2017) 0.75

The Envelope Gene of Transmitted HIV-1 Resists a Late IFNγ-Induced Block. J Virol (2017) 0.75

Type I interferon responses are impaired in latently HIV infected cells. Retrovirology (2016) 0.75

Naturally Occurring Fc-Dependent Antibody From HIV-Seronegative Individuals Promotes HIV-Induced IFN-α Production. Sci Rep (2016) 0.75

Characterization of founder viruses in very early SIV rectal transmission. Virology (2016) 0.75

A Computational Model of Inhibition of HIV-1 by Interferon-Alpha. PLoS One (2016) 0.75

Characterization of Simian Immunodeficiency Virus Variants Anatomically Compartmentalized in Plasma and Milk in Chronically Infected African Green Monkeys. J Virol (2016) 0.75

Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif, Vpr, and Vpu That Are Under Subsequent Immune Pressure During Early Infection. AIDS Res Hum Retroviruses (2016) 0.75

Recent Insights into the HIV/AIDS Pandemic. Microb Cell (2016) 0.75

Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of IFN-α. J Virol (2017) 0.75

Human Immunodeficiency Virus 1 and Type I Interferons-Where Sex Makes a Difference. Front Immunol (2017) 0.75

Articles cited by this

(truncated to the top 100)

How cells respond to interferons. Annu Rev Biochem (1998) 24.27

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

Functional role of type I and type II interferons in antiviral defense. Science (1994) 18.92

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91

Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science (1996) 15.63

A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A (1998) 13.39

A diverse range of gene products are effectors of the type I interferon antiviral response. Nature (2011) 12.86

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08

Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66

The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe (2008) 9.27

Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol (2008) 8.85

Type I interferons in host defense. Immunity (2006) 7.32

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01

Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22

The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99

Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science (1997) 5.91

Targeting early infection to prevent HIV-1 mucosal transmission. Nature (2010) 5.05

Glycerol monolaurate prevents mucosal SIV transmission. Nature (2009) 5.02

Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest (2005) 5.00

Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol (2009) 4.98

The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol (2010) 4.58

Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40

Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24

Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 4.18

Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science (2013) 4.14

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68

Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68

Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60

Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59

Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03

Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature (2012) 2.98

Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95

HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog (2009) 2.92

Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays. Virology (2000) 2.92

Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med (2006) 2.83

The IFITM proteins inhibit HIV-1 infection. J Virol (2010) 2.80

Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75

Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55

APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40

Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. J Exp Med (1976) 2.39

Evidence of dysregulation of dendritic cells in primary HIV infection. Blood (2010) 2.39

Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36

Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses (1991) 2.29

Innate sensing of HIV-infected cells. PLoS Pathog (2011) 2.22

Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog (2010) 2.12

Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05

Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol (2005) 2.01

Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood (2008) 1.99

Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog (2009) 1.99

Control of the interferon-induced 68-kilodalton protein kinase by the HIV-1 tat gene product. Science (1990) 1.93

HIV and HLA class I: an evolving relationship. Immunity (2012) 1.91

Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection. J Immunol (2009) 1.87

HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology (2010) 1.87

Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol (2006) 1.84

Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res (1986) 1.83

Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82

Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol (2006) 1.82

Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80

Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J Virol (2010) 1.79

Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol (2006) 1.67

The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol (2005) 1.67

HIV-1 TAR RNA has an intrinsic ability to activate interferon-inducible enzymes. Virology (1994) 1.63

Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog (2012) 1.61

Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology (2008) 1.57

RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol (2010) 1.55

A selective defect of interferon alpha production in human immunodeficiency virus-infected monocytes. J Exp Med (1990) 1.53

Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol (2009) 1.53

Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis (2010) 1.51

Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog (2012) 1.50

Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol (1990) 1.44

Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res (1994) 1.42

The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. J Virol (2010) 1.42

Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. J Clin Invest (2011) 1.37

Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS (2010) 1.34

Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A (2010) 1.28

Recent advances in understanding viral evasion of type I interferon. Immunology (2013) 1.22

Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B Gag proteins. J Virol (2013) 1.14

Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J Virol (2012) 1.13

Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One (2011) 1.11

Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology (2012) 1.10

Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism. J Virol (2012) 1.05

Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity. J Infect Dis (1996) 1.02

The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR. J Virol (2011) 1.01

Interferon-alpha produces significant decreases in HIV load. J Interferon Cytokine Res (2010) 0.99

Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. J Interferon Cytokine Res (2001) 0.96

Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol (2010) 0.95

Innate immunity in acute HIV-1 infection. Curr Opin HIV AIDS (2011) 0.95

Binding of Tat protein to TAR region of human immunodeficiency virus type 1 blocks TAR-mediated activation of (2'-5')oligoadenylate synthetase. AIDS Res Hum Retroviruses (1990) 0.93

In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response. Ann Intern Med (1992) 0.93

Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine (2008) 0.92

HIV-1 Vpu does not degrade interferon regulatory factor 3. J Virol (2013) 0.92

Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. AIDS (2011) 0.91

Viral evasion of the interferon system. J Interferon Cytokine Res (2009) 0.90

Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression. J Infect Dis (1995) 0.90

Articles by these authors

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91

Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60

Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30

Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS (2003) 8.05

Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60

Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54

Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12

Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12

The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79

Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22

Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep (2008) 6.02

The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99

The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87

Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85

Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol (2005) 5.83

Syphilis in China: results of a national surveillance programme. Lancet (2007) 5.76

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69

Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA (2004) 5.66

Population-based study of chlamydial infection in China: a hidden epidemic. JAMA (2003) 5.40

Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol (2003) 5.36

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35

Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol (2006) 5.25

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol (2008) 5.24

Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol (2009) 4.98

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89

HIV/AIDS risk among brothel-based female sex workers in China: assessing the terms, content, and knowledge of sex work. Sex Transm Dis (2004) 4.88

Acute HIV-1 Infection. N Engl J Med (2011) 4.84

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79

Free access to Landsat imagery. Science (2008) 4.75

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73

Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68

Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature (2003) 4.60

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45

AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44

Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A (2004) 4.37

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35

Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature (2010) 4.35

Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14

Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell (2006) 4.13

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06

Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog (2009) 4.04

Evolutionary relationships of wild hominids recapitulated by gut microbial communities. PLoS Biol (2010) 4.01

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

Hybrid origin of SIV in chimpanzees. Science (2003) 3.75

Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68

Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67

Surplus men, sex work, and the spread of HIV in China. AIDS (2005) 3.64

Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe (2009) 3.58

Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol (2002) 3.58

Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48

Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis (2007) 3.46

HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39

The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol (2007) 3.38

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36

Human immunodeficiency viruses: SIV infection in wild gorillas. Nature (2006) 3.35